Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 1, 2020
Daily News
April 1, 2020
- Post-Promotion Guidelines - 2: Takeda Evaluating “Non-Sales” Factors through Quality Conversations with Bosses
April 1, 2020
- MHLW Orders Label Revisions for Keytruda, Xofluza and More; 1st MID-NET-Based Safety Step Taken
April 1, 2020
- Myovant Licenses European Rights for Relugolix Combo to Gedeon Richter
April 1, 2020
- SanBio Ties Up with China’s Ocumension for Stem Cell Therapies for Eyes
April 1, 2020
- LDP to Suspend Committee Meetings from April 2-12
April 1, 2020
- Govt, LDP Moving to Review Supply Chains in Response to COVID-19 Pandemic
April 1, 2020
- Shionogi Files Xofluza for Post-Exposure Prophylaxis in Taiwan
April 1, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- Astellas Suspends Launch of New Clinical Studies in Virus-Hit Countries
April 1, 2020
- Eiken’s Novel Coronavirus Detection Reagent Kit Approved, with Launch Planned in Mid-April
April 1, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…